Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A Phase 1 Study of Intravenous EGFR-ErbituxEDVSMIT (EEDVSMit) in Children with Recurrent / Refractory Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor (EGFR)
Protocol ID
ECREST
Disease (Sub Disease)
Solid tumours
CNS tumours
CNS tumours
Diagnosis Stage
Relapse/refractory
Sponsor
Sydney Children's Hospital Network
Collaborators
Engeneic Pty Limited
Links
Trial Status
Completed
Trial Close Date
29/12/2021
Study Type
Treatment
Phase
Phase 1
Age Eligibility
2 Years to 21 Years
International registry ID's
NCT02687386
| Study Title | A Phase 1 Study of Intravenous EGFR-ErbituxEDVSMIT (EEDVSMit) in Children with Recurrent / Refractory Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor (EGFR) |
|---|---|
| Protocol ID | ECREST |
| Disease (Sub Disease) | Solid tumours CNS tumours |
| Diagnosis Stage | Relapse/refractory |
| Sponsor | Sydney Children's Hospital Network |
| Collaborators | Engeneic Pty Limited |
| Links | https://clinicaltrials.gov/ct2/show/NCT02687386 |
| Trial Status | Completed |
| Trial Open Date | 08/02/2016 |
| Trial Close Date | 29/12/2021 |
| Study Type | Treatment |
| Phase | Phase 1 |
| Age Eligibility | 2 Years to 21 Years |
| International registry ID's | NCT02687386 |